Not All Coronary Spasms Are the Same: Benefits of Acetylcholine

Patients with documented spasm to the coronary arteries present increased risk of myocardial infarction (MI) and repeat angiography, while patients with microvascular spasm are associated to recurrent angina. 

¿FFR de rutina en pacientes con síndrome coronario agudo?

Globally, the prognosis of all these patients continues to be favourable, even though acetylcholine testing might help distinguish one-another. 

Coronary spasm shows in up to 60% of patients with myocardial ischemia symptoms despite not presenting obstructive coronary lesions. 

This recent study published in JACC Interv retrospectively included consecutive patients with no obstructive coronary lesions undergoing acetylcholine testing for epicardial or microvascular spasm detection. 

Mortality, non-fatal MI, stroke, repeat angiography, recurrent symptoms, and quality of life of 736 patients were registered and followed up for 7.2 years.


Read also: IN.PACT AV ACCESS | Drug-Coated Balloons for Dialysis Fistulas.


Mortality in this followup period was 7.5%, non-fatal MI rate was 1.4%, and stroke reached 2.2%. 

Most patients reported recurrent angina (64%). This motivated repeat angiography (12%) which, same as before, showed no obstructive lesions.

Epicardial spasm was a predictor of non-fatal MI (HR: 14.4) and repeat angiography (HR: 1.7), while microvascular spasm predicted more symptoms (HR: 1.3).

Conclusion

The general prognosis of patients with coronary spasm is favourable. Acetylcholine testing helped identify patients with epicardial MI, with higher risk of non-fatal MI and repeat angiographies vs. patients with microvascular spasm associated to higher risk of recurrent angina. 

Original Title: Long-Term Follow-Up in Patients With Stable Angina and Unobstructed Coronary Arteries Undergoing Intracoronary Acetylcholine Testing.

Reference: Andreas Seitz et al. JACC Cardiovasc Interv. 2020 Aug 24;13(16):1865-1876. https://doi.org/10.1016/j.jcin.2020.05.009.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....